Used as a key intermediate in the synthesis of epidermal growth factor receptor (EGFR) inhibitors, particularly in targeted cancer therapies. Its structure enables selective binding to mutant forms of EGFR, making it valuable in the development of drugs for non-small cell lung cancer (NSCLC). The compound's nitro and fluoro groups enhance binding affinity, while the pyridinylmethoxy moiety improves pharmacokinetic properties. It is primarily employed in research and pharmaceutical development for oncology applications, especially in creating irreversible tyrosine kinase inhibitors.